Anhui Anke Biotechnology (Group) Co., Ltd. (SHE:300009)

Market Cap	14.77B +12.9%
Revenue (ttm)	2.56B +2.0%
Net Income	693.78M -0.6%
EPS	0.42 +2.1%
Shares Out	1.67B
PE Ratio	21.13
Forward PE	18.85
Dividend	0.25 (2.82%)
Ex-Dividend Date	n/a

Volume	18,488,607
Average Volume	20,462,331
Open	8.82
Previous Close	8.79
Day's Range	8.80 - 8.94
52-Week Range	8.18 - 13.06
Beta	0.38
RSI	34.28
Earnings Date	Aug 25, 2026

About SHE:300009

Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. The company provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life det...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 2,505
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300009

Financial Performance

In 2025, SHE:300009's revenue was 2.65 billion, an increase of 4.36% compared to the previous year's 2.54 billion. Earnings were 735.19 million, an increase of 4.00%.